Alexander Heckman, MD
Cardiovascular Disease · Clearwater, FLNPI 1811341746
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $681 of the $1,014 with a category attached, or 67.1%. 9 manufacturers reported payments, led by Angiodynamics, Inc. at 32.9% of the total. That places this record below the midpoint for cardiovascular disease clinicians in FL, where the typical reported total is $2,774.
Across 15 payments — averaging $67.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$333
- Cardiovascular Systems Inc.$148
- Abbott$111
- GE HealthCare$100
- Boston Scientific$98
- Chiesi USA, Inc.$79
- plus $145 from 3 others
Across 1 payment — averaging $29,457 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$29K
What the payments were for
- Food & beverage$68167%
- Other$33333%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 1 | $333 |
| Cardiovascular Systems Inc. | 1 | $148 |
| Abbott | 3 | $111 |
| GE HealthCare | 1 | $100 |
| Boston Scientific | 1 | $98 |
| Chiesi USA, Inc. | 1 | $79 |
| Amgen | 4 | $60 |
| Abiomed | 1 | $47 |
| AstraZeneca | 2 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,014 in reported general payments places this provider in the 30th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $10,313 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 29 | $451 |
| Atorvastatin Calcium | 31 | $298 |
| Metoprolol Succinate | 28 | $263 |
| Amlodipine Besylate | 24 | $224 |
| ClopidogrelClopidogrel Bisulfate | 23 | $207 |
| Rosuvastatin Calcium | 11 | $111 |
| Metoprolol Tartrate | 12 | $65 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Clearwater
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.